[go: up one dir, main page]

CL2008000316A1 - Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara - Google Patents

Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara

Info

Publication number
CL2008000316A1
CL2008000316A1 CL200800316A CL2008000316A CL2008000316A1 CL 2008000316 A1 CL2008000316 A1 CL 2008000316A1 CL 200800316 A CL200800316 A CL 200800316A CL 2008000316 A CL2008000316 A CL 2008000316A CL 2008000316 A1 CL2008000316 A1 CL 2008000316A1
Authority
CL
Chile
Prior art keywords
compounds
catara
metilsulfonil
tetrahydroisoquinoline
hyperlipidemia
Prior art date
Application number
CL200800316A
Other languages
English (en)
Inventor
Philip B Azimioara Mihai Alper
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39356580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of CL2008000316A1 publication Critical patent/CL2008000316A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
CL200800316A 2007-02-02 2008-02-01 Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara CL2008000316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88803307P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
CL2008000316A1 true CL2008000316A1 (es) 2008-08-08

Family

ID=39356580

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800316A CL2008000316A1 (es) 2007-02-02 2008-02-01 Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara

Country Status (15)

Country Link
US (2) US20080186971A1 (es)
EP (1) EP2114890A2 (es)
JP (1) JP2010518001A (es)
KR (1) KR20090114428A (es)
CN (1) CN101663278A (es)
AR (1) AR065133A1 (es)
AU (1) AU2008214440A1 (es)
BR (1) BRPI0808192A2 (es)
CA (1) CA2677263A1 (es)
CL (1) CL2008000316A1 (es)
EA (1) EA200901032A1 (es)
MX (1) MX2009008159A (es)
PE (1) PE20090057A1 (es)
TW (1) TW200836736A (es)
WO (1) WO2008097428A2 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8799466B2 (en) * 2005-01-31 2014-08-05 Hewlett-Packard Development Company, L.P. Method and apparatus for automatic verification of a network access control construct for a network switch
WO2008008887A2 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
EA201001329A1 (ru) * 2008-02-22 2011-04-29 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
US8346697B2 (en) * 2008-10-31 2013-01-01 International Business Machines Corporation Direct construction of finite state machines
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP5332854B2 (ja) * 2009-04-20 2013-11-06 ソニー株式会社 無線送信機、無線送信方法、無線受信機および無線受信方法
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2445343B1 (en) * 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
AU2011326071A1 (en) 2010-11-08 2013-05-23 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
FI3156056T3 (fi) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Sorbitaaniestereitä käsittäviä farmaseuttisia koostumuksia
AU2012240122B2 (en) * 2011-04-08 2016-08-25 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US9110703B2 (en) * 2011-06-07 2015-08-18 Hewlett-Packard Development Company, L.P. Virtual machine packet processing
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
CN102659675A (zh) * 2011-12-27 2012-09-12 盛世泰科生物医药技术(苏州)有限公司 6-溴-2-甲基磺酰基-1,2,3,4,-四氢异喹啉的一种合成方法
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9549413B2 (en) * 2012-03-30 2017-01-17 Nec Corporation Control apparatus, communication apparatus, communication method and program
HK1200821A1 (en) 2012-04-04 2015-08-14 霍夫曼-拉罗奇有限公司 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US20140379915A1 (en) * 2013-06-19 2014-12-25 Cisco Technology, Inc. Cloud based dynamic access control list management architecture
KR101984281B1 (ko) * 2013-08-08 2019-05-31 동아에스티 주식회사 Gpr119 작용 활성을 갖는 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
NZ720004A (en) 2013-11-18 2020-03-27 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CA2939305A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
CN108463459A (zh) 2014-09-25 2018-08-28 圣母大学 非β-内酰胺类抗生素
CN104447693B (zh) * 2014-10-24 2016-08-24 苏州昊帆生物科技有限公司 喹啉酮衍生物及其制备方法和应用
CN104592215A (zh) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 一种哌啶取代恶二唑衍生物的制备方法
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CN104610390A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途
CN104610393A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途
CN104876918A (zh) * 2015-04-23 2015-09-02 湖南华腾制药有限公司 一种吡嗪取代恶二唑化合物的制备方法
CN104788386A (zh) * 2015-04-24 2015-07-22 湖南华腾制药有限公司 一种含氟嘧啶化合物的制备方法
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en) 2015-06-11 2022-04-20 The Regents of the University of Michigan Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CA3002846A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof
WO2017075185A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017075182A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018049404A1 (en) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Compounds for the treatment of clostridium difficile infection
US10404594B2 (en) 2016-12-13 2019-09-03 Oracle International Corporation System and method for providing partitions of classification resources in a network device
US10341242B2 (en) * 2016-12-13 2019-07-02 Oracle International Corporation System and method for providing a programmable packet classification framework for use in a network device
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
AU2018351059B2 (en) 2017-10-19 2022-05-12 Teijin Pharma Limited Benzimidazole derivatives and their uses
KR102777148B1 (ko) 2017-12-19 2025-03-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
US11319315B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
SG11202005699QA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US12428430B2 (en) 2018-09-18 2025-09-30 Bristol-Myers Squibb Company Oxabicyclo acids as LPA antagonists
EP3852747B1 (en) 2018-09-18 2023-05-31 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
JP7427658B2 (ja) 2018-09-18 2024-02-05 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロペンチル酸
KR102661806B1 (ko) * 2018-11-27 2024-04-30 삼성전자주식회사 디스플레이 장치의 제어 방법 및 그에 따른 디스플레이 장치
JP2022515990A (ja) * 2018-12-10 2022-02-24 ドライブネッツ リミテッド 通信ネットワークにおけるトラフィックフローをモニタリングするシステム及び方法
CN109761990B (zh) * 2019-01-30 2019-12-24 江西中医药大学 一种嘧啶并嘧啶类衍生物及其制备方法和在医药上的应用
JP7465899B2 (ja) 2019-06-18 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸
US12435057B2 (en) 2019-06-18 2025-10-07 Bristol-Myers Squibb Company Triazole carboxylic acids as LPA antagonists
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
AU2021275118A1 (en) 2020-05-22 2022-12-01 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
JP2023539463A (ja) 2020-08-17 2023-09-14 アリゴス セラピューティクス インコーポレイテッド Ｐｄ－ｌ１を標的とするための方法及び組成物
WO2022242750A1 (zh) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
JP2000515501A (ja) * 1996-07-01 2000-11-21 イーライ・リリー・アンド・カンパニー 低血糖化および低脂血化用化合物群
US5912342A (en) * 1997-08-12 1999-06-15 Heinonen; Petri Compounds a containing a solid support
US5995971A (en) * 1997-09-18 1999-11-30 Micdrosoft Corporation Apparatus and accompanying methods, using a trie-indexed hierarchy forest, for storing wildcard-based patterns and, given an input key, retrieving, from the forest, a stored pattern that is identical to or more general than the key
EP0937723A1 (de) * 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
HUP0101137A3 (en) * 1998-04-10 2003-03-28 Japan Tobacco Inc Anticoagulant amidines and their pharmaceutical use
US6658002B1 (en) * 1998-06-30 2003-12-02 Cisco Technology, Inc. Logical operation unit for packet processing
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6643260B1 (en) * 1998-12-18 2003-11-04 Cisco Technology, Inc. Method and apparatus for implementing a quality of service policy in a data communications network
US6651096B1 (en) * 1999-04-20 2003-11-18 Cisco Technology, Inc. Method and apparatus for organizing, storing and evaluating access control lists
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US7028096B1 (en) * 1999-09-14 2006-04-11 Streaming21, Inc. Method and apparatus for caching for streaming data
US7058728B1 (en) * 1999-10-29 2006-06-06 Nokia Corporation Method and apparatus for initiating compression of headers of packets and refreshing the context related to the packets
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
HUP0203431A3 (en) * 1999-12-03 2003-11-28 Kyoto Pharma Ind Novel heterocyclic compounds and salts thereof and pharmaceutical compositions containing and use of the same
US6798746B1 (en) * 1999-12-18 2004-09-28 Cisco Technology, Inc. Method and apparatus for implementing a quality of service policy in a data communications network
US6977930B1 (en) * 2000-02-14 2005-12-20 Cisco Technology, Inc. Pipelined packet switching and queuing architecture
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
ATE491288T1 (de) * 2000-06-09 2010-12-15 Broadcom Corp Flexibler protokoll-header für netzwerk-switch
US6658458B1 (en) * 2000-06-22 2003-12-02 Cisco Technology, Inc. Cascading associative memory arrangement
US7051078B1 (en) * 2000-07-10 2006-05-23 Cisco Technology, Inc. Hierarchical associative memory-based classification system
US6952425B1 (en) * 2000-11-14 2005-10-04 Cisco Technology, Inc. Packet data analysis with efficient and flexible parsing capabilities
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7096256B1 (en) * 2001-02-26 2006-08-22 Juniper Network, Inc. Applying configuration group information to target configuration information
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US7002965B1 (en) * 2001-05-21 2006-02-21 Cisco Technology, Inc. Method and apparatus for using ternary and binary content-addressable memory stages to classify packets
US7065083B1 (en) * 2001-10-04 2006-06-20 Cisco Technology, Inc. Method and apparatus for dynamically generating lookup words for content-addressable memories
US6775737B1 (en) * 2001-10-09 2004-08-10 Cisco Technology, Inc. Method and apparatus for allocating and using range identifiers as input values to content-addressable memories
US7133914B1 (en) * 2001-10-31 2006-11-07 Cisco Technology, Inc. Statistics-preserving ACL flattening system and method
US7224968B2 (en) * 2001-11-23 2007-05-29 Actix Limited Network testing and monitoring systems
US6957215B2 (en) * 2001-12-10 2005-10-18 Hywire Ltd. Multi-dimensional associative search engine
JP2005518376A (ja) * 2001-12-14 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 化合物およびホルモン感受性リパーゼの活性を低下させるためのその使用
US6715029B1 (en) * 2002-01-07 2004-03-30 Cisco Technology, Inc. Method and apparatus for possibly decreasing the number of associative memory entries by supplementing an associative memory result with discriminator bits from an original set of information
US6970971B1 (en) * 2002-01-08 2005-11-29 Cisco Technology, Inc. Method and apparatus for mapping prefixes and values of a hierarchical space to other representations
US7154888B1 (en) * 2002-02-08 2006-12-26 Cisco Technology, Inc. Method for classifying packets using multi-class structures
DE60325025D1 (de) * 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US6871265B1 (en) * 2002-02-20 2005-03-22 Cisco Technology, Inc. Method and apparatus for maintaining netflow statistics using an associative memory to identify and maintain netflows
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US6867991B1 (en) * 2003-07-03 2005-03-15 Integrated Device Technology, Inc. Content addressable memory devices with virtual partitioning and methods of operating the same
US7236493B1 (en) * 2002-06-13 2007-06-26 Cisco Technology, Inc. Incremental compilation for classification and filtering rules
US7065367B2 (en) * 2002-07-11 2006-06-20 Oliver Michaelis Interface selection in a wireless communication network
US7028136B1 (en) * 2002-08-10 2006-04-11 Cisco Technology, Inc. Managing idle time and performing lookup operations to adapt to refresh requirements or operational rates of the particular associative memory or other devices used to implement the system
US7103708B2 (en) * 2002-08-10 2006-09-05 Cisco Technology, Inc. Performing lookup operations using associative memories optionally including modifying a search key in generating a lookup word and possibly forcing a no-hit indication in response to matching a particular entry
US7065609B2 (en) * 2002-08-10 2006-06-20 Cisco Technology, Inc. Performing lookup operations using associative memories optionally including selectively determining which associative memory blocks to use in identifying a result and possibly propagating error indications
US7082492B2 (en) * 2002-08-10 2006-07-25 Cisco Technology, Inc. Associative memory entries with force no-hit and priority indications of particular use in implementing policy maps in communication devices
ES2392200T3 (es) * 2002-09-19 2012-12-05 Eli Lilly & Company Ésteres de diarilo como antagonistas del receptor opiáceo
MXPA05002003A (es) * 2002-09-26 2005-08-03 Warner Lambert Co Piperazinas sustituidas heterociclicas para el tratamiento de la esquizofrenia.
US7093092B2 (en) * 2002-12-10 2006-08-15 Isic Corporation Methods and apparatus for data storage and retrieval
US7584303B2 (en) * 2002-12-20 2009-09-01 Forte 10 Networks, Inc. Lossless, stateful, real-time pattern matching with deterministic memory resources
US7043494B1 (en) * 2003-01-28 2006-05-09 Pmc-Sierra, Inc. Fast, deterministic exact match look-ups in large tables
ES2297386T3 (es) * 2003-03-03 2008-05-01 F. Hoffmann-La Roche Ag Tetrahidroisoquinolinas 2,5-sustituidas para uso como moduladores de 5-ht6.
JP4728962B2 (ja) * 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
US7313827B2 (en) * 2003-07-10 2007-12-25 International Business Machines Corporation Apparatus and method for analysis of conversational patterns to position information and autonomic access control list management
US20050114700A1 (en) * 2003-08-13 2005-05-26 Sensory Networks, Inc. Integrated circuit apparatus and method for high throughput signature based network applications
US7080195B2 (en) * 2003-10-22 2006-07-18 Cisco Technology, Inc. Merging indications of matching items of multiple groups and possibly associated with skip conditions to identify winning entries of particular use for implementing access control lists
MXPA06007654A (es) * 2003-12-31 2006-09-04 Warner Lambert Co Derivados de piperidina n-sustituidos.
US7356663B2 (en) * 2004-11-08 2008-04-08 Intruguard Devices, Inc. Layered memory architecture for deterministic finite automaton based string matching useful in network intrusion detection and prevention systems and apparatuses
WO2006071940A2 (en) * 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
WO2006073980A2 (en) * 2005-01-06 2006-07-13 Tervela, Inc. Hardware-based messaging appliance
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US8980915B2 (en) * 2005-04-19 2015-03-17 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and apo-B secretion
JP2008540539A (ja) * 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
WO2007050124A1 (en) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
US7499941B2 (en) * 2005-09-05 2009-03-03 Cisco Technology, Inc. Pipeline regular expression matching
US7790745B2 (en) * 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US20070111981A1 (en) * 2005-10-26 2007-05-17 Roth Gerald J New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
US7778972B1 (en) * 2005-12-29 2010-08-17 Amazon Technologies, Inc. Dynamic object replication within a distributed storage system
KR20090047518A (ko) * 2006-08-09 2009-05-12 콸콤 인코포레이티드 단순화된 소켓 인터페이스를 통해 브로드캐스트/멀티캐스트ｉｐ 패킷들을 지원하기 위한 장치 및 방법
CN101522614B (zh) * 2006-08-09 2014-06-25 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的化合物
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US7899976B2 (en) * 2006-12-08 2011-03-01 Pandya Ashish A FSA extension architecture for programmable intelligent search memory

Also Published As

Publication number Publication date
AR065133A1 (es) 2009-05-20
US20080186971A1 (en) 2008-08-07
WO2008097428A2 (en) 2008-08-14
CA2677263A1 (en) 2008-08-14
US20100022515A1 (en) 2010-01-28
JP2010518001A (ja) 2010-05-27
PE20090057A1 (es) 2009-02-13
CN101663278A (zh) 2010-03-03
EP2114890A2 (en) 2009-11-11
KR20090114428A (ko) 2009-11-03
BRPI0808192A2 (pt) 2019-09-24
EA200901032A1 (ru) 2010-02-26
MX2009008159A (es) 2009-10-08
AU2008214440A1 (en) 2008-08-14
TW200836736A (en) 2008-09-16
WO2008097428A3 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
CL2008000316A1 (es) Compuestos derivados de 2-metilsulfonil-1,2,3,4-tetrahidroisoquinolina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la diabetes, hiperlipidemia, enfermedades cardiacas, artritis, osteoporosis, hipertension, catara
CL2008000703A1 (es) Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008000369A1 (es) Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas.
CL2007002834A1 (es) Compuestos derivados de pirazina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos relacionados con inflamacion, tales como artritis, intestino inflamado, alergia,
CL2008000330A1 (es) Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.
CL2008000252A1 (es) Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
CL2007002446A1 (es) Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
CL2007003874A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
CL2007002904A1 (es) Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
CL2007002791A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri
CL2008000094A1 (es) Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion.
CL2007003176A1 (es) Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis.
CL2007003755A1 (es) Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
CL2008000887A1 (es) Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de
CL2008000585A1 (es) Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds.
CL2008001372A1 (es) Compuestos derivados de pirazol sustituidos con heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos hiperproliferativos y enfermedades relacionadas con angiogenesis.
CL2007003502A1 (es) Compuestos derivados de pirimidin-amina, moduladores de jnk; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento de artritis reumatoide, asma, diabetes tipo ii, enfermedad de alzheimer, enfermedad de parkinson y apoplejia.
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2008000754A1 (es) Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
CL2008000067A1 (es) Compuestos derivados de espirocromanona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, higado graso, hiperlipemia, obesidad, diabetes, bulimia, neoplasma maligno o enfermedades infecciosas.